Skip to content
2000
Volume 25, Issue 6
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Heterocyclic compounds are increasingly used in medicinal chemistry because they are the main components of many biological processes and materials. Benzimidazole remains the core center of the heterocyclic chemical group, with essential traits such as six-five-member connected rings and two nitrogen atoms at the 1,3 position in a six-membered benzene and five-membered imidazole-fused ring system. Molecules with benzimidazole derivatives serve important functions as therapeutic agents and have shown excellent results in clinical and biological research. In this comprehensive review, we summarize marketed medications that include the benzimidazole moiety. Here, we discuss two topics: PPIs and H receptor antagonists. Benzimidazole derivatives are important in all fields because they have the same isostructural pharmacophore as that of naturally occurring active biomolecules. While PPIs and H1 receptor antagonists are generally safe in the short term, accumulating data suggest that their long-term use may pose concerns. This systematic review aimed to assess global PPI use in the general population. This will help researchers, medicinal chemists, and pharmaceutical scientists to create breakthrough benzimidazole-based drugs. This review can help identify novel lead compounds and optimize existing benzimidazole derivatives to improve medicinal efficacy. Benzimidazole has attracted significant interest because of its high bioavailability, stability, and biological efficiency. This page reveals and discusses typical synthesis processes for marketed pharmaceuticals in the benzimidazole class of scaffolds, MOA, and therapeutic uses.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575329633240928163509
2025-01-06
2025-10-08

  • From This Site

    /content/journals/mrmc/10.2174/0113895575329633240928163509
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AnandK. WakodeS. Development of drugs based on benzimidazole heterocycle: Recent advancement and insights. Inter.J. Chem. Sci.201752350362
     [Google Scholar]
  2. WrightJ.B. The chemistry of the benzimidazoles.Chem. Rev.195148339754110.1021/cr60151a00224541208
     [Google Scholar]
  3. KeriR.S. HiremathadA. BudagumpiS. NagarajaB.M. Comprehensive review in current developments of benzimidazole-based medicinal chemistry.Chem. Biol. Drug Des.2015861196510.1111/cbdd.1246225352112
     [Google Scholar]
  4. LeeY.T. TanY.J. OonC.E. Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine.Acta Pharm. Sin. B202313247849710.1016/j.apsb.2022.09.01036873180
     [Google Scholar]
  5. MoraisG.R. PalmaE. MarquesF. GanoL. OliveiraM.C. AbrunhosaA. MirandaH.V. OuteiroT.F. SantosI. PauloA. Synthesis and biological evaluation of novel 2-aryl benzimidazoles as chemotherapeutic agents.J. Heterocycl. Chem.201754125526710.1002/jhet.2575
     [Google Scholar]
  6. PiseP.P. BochareV.K. BodakeR.S. BelhekarA.B. GaikwadS. A review on synthesis and characterisation of benzimidazole.Int. Adv. Res. Sci. Commun. Technol.202221455010.48175/IJARSCT‑5644
     [Google Scholar]
  7. ElderfieldRC Heterocyclic Compounds: Five-membered heterocycles containing two hetero atoms and their benzo derivatives.Wiley19755
     [Google Scholar]
  8. WaliaR. HedaitullahMd. NaazS.F. IqbalK. LambaH.S. Benzimidazole derivatives: An overview.Int. J. Res. Pharm. Chem.201113565574
     [Google Scholar]
  9. BarotK. NikolovaS. IvanovI. GhateM. Novel research strategies of benzimidazole derivatives: A review.Mini Rev. Med. Chem.201313101421144710.2174/1389557511313999007223544603
     [Google Scholar]
  10. AlaqeelS.I. Synthetic approaches to benzimidazoles from o-phenylenediamine: A literature review.J. Saudi Chem. Soc.201721222923710.1016/j.jscs.2016.08.001
     [Google Scholar]
  11. BrishtyS.R. HossainM.J. KhandakerM.U. FaruqueM.R.I. OsmanH. RahmanS.M.A. A comprehensive account on recent progress in pharmacological activities of benzimidazole derivatives.Front. Pharmacol.20211276280710.3389/fphar.2021.76280734803707
     [Google Scholar]
  12. WoolleyD.W. Some biological effects produced by benzimidazole and their reversal by purines.J. Biol. Chem.1944152222523210.1016/S0021‑9258(18)72045‑0
     [Google Scholar]
  13. PathareB. BansodeT. Review - Biological active benzimidazole derivatives.Results Chem.2021310020010.1016/j.rechem.2021.100200
     [Google Scholar]
  14. BansalY. SilakariO. The therapeutic journey of benzimidazoles: A review.Bioorg. Med. Chem.201220216208623610.1016/j.bmc.2012.09.01323031649
     [Google Scholar]
  15. FeiF. ZhouZ. New substituted benzimidazole derivatives: A patent review (2010 – 2012).Expert Opin. Ther. Pat.20132391157117910.1517/13543776.2013.80085723675911
     [Google Scholar]
  16. WangM. HanX. ZhouZ. New substituted benzimidazole derivatives: A patent review (2013 – 2014).Expert Opin. Ther. Pat.201525559561210.1517/13543776.2015.101598725887338
     [Google Scholar]
  17. PatilA. GangulyS. SuranaS. A systemic review on benzimidazole derivatives as a antiulcer agents.Rasayan J. Chem.200813447460
     [Google Scholar]
  18. PalitR. KumarR. SaraswatN. WalA. UpadhyayaP.K. Benzimidazole: An overview.Int. J. Res. Ayurveda Pharm.201776687310.7897/2277‑4343.076243
     [Google Scholar]
  19. SachsG. ShinJ.M. BrivingC. WallmarkB. HerseyS. The pharmacology of the gastric acid pump: The H+,K+ ATPase.Annu. Rev. Pharmacol. Toxicol.199535127730510.1146/annurev.pa.35.040195.0014257598495
     [Google Scholar]
  20. ShiS. KlotzU. Proton pump inhibitors: An update of their clinical use and pharmacokinetics.Eur. J. Clin. Pharmacol.2008641093595110.1007/s00228‑008‑0538‑y18679668
     [Google Scholar]
  21. SchubertM.L. PeuraD.A. Control of gastric acid secretion in health and disease.Gastroenterology200813471842186010.1053/j.gastro.2008.05.02118474247
     [Google Scholar]
  22. JainK.S. ShahA.K. BariwalJ. ShelkeS.M. KaleA.P. JagtapJ.R. BhosaleA.V. Recent advances in proton pump inhibitors and management of acid-peptic disorders.Bioorg. Med. Chem.20071531181120510.1016/j.bmc.2006.07.06817150362
     [Google Scholar]
  23. CampbellD.R. HurwitzA. ParkinsonA. Proton pump inhibitors.Current Clinical Topics in Gastrointestinal PharmacologyWiley-Blackwell LewisJ.H. DuboisA. 1997303324
     [Google Scholar]
  24. RichardsonP. HawkeyC.J. StackW.A. Proton pump inhibitors: Pharmacology and rationale for use in gastrointestinal disorders.Drugs199856330733510.2165/00003495‑199856030‑000029777309
     [Google Scholar]
  25. SachsG. Proton pump inhibitors and acid-related diseases.Pharmacotherapy1997171223710.1002/j.1875‑9114.1997.tb03675.x9017763
     [Google Scholar]
  26. KromerW. HorbachS. LühmannR. Relative efficacies of gastric proton pump inhibitors: Their clinical and pharmacological basis.Pharmacol.1999592577710.1159/00002830610450061
     [Google Scholar]
  27. ScarpignatoC. HuntR. Proton pump inhibitors: The beginning of the end or the end of the beginning?Curr. Opin. Pharmacol.20088667768410.1016/j.coph.2008.09.00418840545
     [Google Scholar]
  28. SpectorR. VesellE.S. The power of pharmacological sciences: The example of proton pump inhibitors.Pharmacol.200676314815610.1159/00009125916449824
     [Google Scholar]
  29. ChongE. EnsomM.H.H. Pharmacogenetics of the proton pump inhibitors: A systematic review.Pharmacotherapy200323446047110.1592/phco.23.4.460.3212812680476
     [Google Scholar]
  30. El RoubyN. LimaJ.J. JohnsonJ.A. Proton pump inhibitors: From CYP2C19 pharmacogenetics to precision medicine.Expert Opin. Drug Metab. Toxicol.201814444746010.1080/17425255.2018.146183529620484
     [Google Scholar]
  31. ModakA.S. KlyarytskaI. KriviyV. TsapyakT. RabotyagovaY. The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole- 13 C breath test in GERD patients: Clinical relevance for personalized medicine.J. Breath Res.201610404601710.1088/1752‑7163/10/4/04601727991432
     [Google Scholar]
  32. KouE. ZhangX. DongB. WangB. ZhuY. Combination of H1 and H2 histamine receptor antagonists: Current knowledge and perspectives of a classic treatment strategy.Life (Basel)202414216410.3390/life1402016438398673
     [Google Scholar]
  33. PanulaP. ChazotP.L. CowartM. GutzmerR. LeursR. LiuW.L.S. StarkH. ThurmondR.L. HaasH.L. International union of basic and clinical pharmacology. XCVIII. Histamine Receptors.Pharmacol. Rev.201567360165510.1124/pr.114.01024926084539
     [Google Scholar]
  34. HillS.J. Distribution, properties, and functional characteristics of three classes of histamine receptor.Pharmacol. Rev.199042145832164693
     [Google Scholar]
  35. SimonsF.E.R. SimonsK.J. H1 Antihistamines.World Allergy Organ. J.20081914515510.1097/WOX.0b013e318186fb3a23282578
     [Google Scholar]
  36. ChuZ. CenL. XuQ. LinG. MoJ. ShaoL. ZhaoY. LiJ. YeW. FangT. RenW. ZhuQ. HeG. XuY. Discovery of the novel and potent histamine H1 receptor antagonists for treatment of allergic diseases.Eur. J. Med. Chem.202426811619710.1016/j.ejmech.2024.11619738368709
     [Google Scholar]
  37. HbibiA. RileyE.T. Antihistamines: H1- and H2- blockers.Complication in AnesthesiaSaunders ElsevierUSA2nd ed2007
     [Google Scholar]
  38. GabaM. MohanC. Development of drugs based on imidazole and benzimidazole bioactive heterocycles: Recent advances and future directions.Med. Chem. Res.201625217321010.1007/s00044‑015‑1495‑5
     [Google Scholar]
  39. LaineL. HennekensC. Proton pump inhibitor and clopidogrel interaction: Fact or fiction?Am. J. Gastroenterol.20101051344110.1038/ajg.2009.63819904241
     [Google Scholar]
  40. VakilN. Prescribing proton pump inhibitors: Is it time to pause and rethink?Drugs201272443744510.2165/11599320‑000000000‑0000022356286
     [Google Scholar]
  41. HornJ. The proton-pump inhibitors: Similarities and differences.Clin. Ther.200022326628010.1016/S0149‑2918(00)80032‑610963283
     [Google Scholar]
  42. AbrahamiD. McDonaldE.S. SchnitzerM.E. BarkunA.N. SuissaS. AzoulayL. Proton pump inhibitors and risk of gastric cancer: Population based cohort study.Gut2022711162410.1136/gutjnl‑2021‑325097
     [Google Scholar]
  43. StrandD.S. KimD. PeuraD.A. 25 years of proton pump inhibitors: A comprehensive review.Gut Liver2017111273710.5009/gnl1550227840364
     [Google Scholar]
  44. VardanyanR. HrubyV. Synthesis of best-seller drugs.Proton Pump InhibitorsElsevier201676578110.1016/B978‑0‑12‑411492‑0.00037‑7
     [Google Scholar]
  45. Scriven EricF.V. Pyridines: From Lab to Production.Elsevier1st ed201310.1016/B978‑0‑12‑385235‑9.00001‑1
     [Google Scholar]
  46. SainiS. MajeeC. ChakraborthyG.S. Salahuddin Novel synthesis of omeprazole and pharmaceutical impurities of proton pump inhibitors: A review.Int. J. Pharm. Tech. Res.2019123577010.20902/IJPTR.2019.120307
     [Google Scholar]
  47. HowdenC.W. Clinical pharmacology of omeprazole.Clin. Pharmacokinet.1991201384910.2165/00003088‑199120010‑000032029801
     [Google Scholar]
  48. SachsG. ShinJ.M. HowdenC.W. Review article: The clinical pharmacology of proton pump inhibitors.Aliment. Pharmacol. Ther.200623s22810.1111/j.1365‑2036.2006.02943.x16700898
     [Google Scholar]
  49. CarlssonE. LindbergP. UngeV.S. Two of a kind.Chem. Br.2002384245
     [Google Scholar]
  50. Omeprazole.2024Available from: https://www.drugs.com/omeprazole.html
  51. KhomenkoT.M. VolchoK.P. KomarovaN.I. SalakhutdinovN.F. An efficient procedure for the synthesis of Esomeprazole using a titanium complex with two chiral ligands.Russ. J. Org. Chem.200844112412710.1134/S1070428008010168
     [Google Scholar]
  52. McAllisterG.D. ParsonsA.F. Going green in process chemistry: Optimizing an asymmetric oxidation reaction to synthesize the antiulcer drug esomeprazole.J. Chem. Educ.201996112617262110.1021/acs.jchemed.9b0035032051644
     [Google Scholar]
  53. Esomeprazole.2024Available from: https://www.pediatriconcall.com/drugs/esomeprazole/550
  54. DeanL. KaneM. Omeprazole therapy and CYP2C19 genotype202128520353
     [Google Scholar]
  55. GangulaS. ElatiC.R. NeredlaA. BaddamS.R. NeelamU.K. BandichhorR. DongamantiA. An improved process for the production of lansoprazole: Investigation of key parameters that influence the water content in final API.Org. Process Res. Dev.201014122923310.1021/op900258b
     [Google Scholar]
  56. ReddyG.M. MukkantiK. KumarT.L. BabuJ.M. ReddyP.P. Synthesis and characterization of metabolites and potential impurities of lansoprazole, an antiulcerative drug.Synth. Commun.200838203477348910.1080/00397910802162934
     [Google Scholar]
  57. BosnjakT. SolbergR. HematiP.D. JafariA. KassemM. JohansenH.T. Lansoprazole inhibits the cysteine protease legumain by binding to the active site.Basic Clin. Pharmacol. Toxicol.20191252899910.1111/bcpt.1323030916878
     [Google Scholar]
  58. GarnettW.R. Lansoprazole: A proton pump inhibitor.Ann. Pharmacother.199630121425143610.1177/1060028096030012128968456
     [Google Scholar]
  59. Lansoprazole.2024Available from: https://www.drugs.com/lansoprazole.html
  60. PitchenP. DunachE. DeshmukhM.N. KaganH.B. An efficient asymmetric oxidation of sulfides to sulfoxides.J. Am. Chem. Soc.1984106268188819310.1021/ja00338a030
     [Google Scholar]
  61. AttolinoE. LucchiniV. Process for the preparation of dexlansoprazole.US Patent US 2010/0125143 A1, March 202010
  62. RajuM.N. KumarN.U. ReddyB.S. AnithaN. SrinivasG. BhattacharyaA. MukkantiK. KollaN. BandichhorR. An efficient synthesis of dexlansoprazole employing asymmetric oxidation strategy.Tetrahedron Lett.201152425464546610.1016/j.tetlet.2011.08.033
     [Google Scholar]
  63. SatyanarayanaR.M. EswaraiahS. VenkateshM. Process for the preparation of dex¬lansoprazole via S-oxidation of N-camphorsulfonyl lansoprazole sulfide precursor.WO Patent 20100951442012
  64. Von UngeS. Optical purification of enantiomerically enriched 2-[(arylmethyl)sulfinyl]benz¬imidazole derivatives.WO Patent 97022611977
  65. ShinJ.M. KimN. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.J. Neurogastroenterol. Motil.2013191253510.5056/jnm.2013.19.1.2523350044
     [Google Scholar]
  66. Dexlansoprazole (oral route).2024Available from: https://www.mayoclinic.org/drugs-supplements/dexlansoprazole-oral-route/description/drg-20072564
  67. YariA. ZolaliA. KarimianK. On the mechanism of formation and the synthesis of pantoprazole sodium sesquihydrate-related compound: A phantom chemical entity.ACS Omega20194173774410.1021/acsomega.8b0084531459358
     [Google Scholar]
  68. KankanR.N. SrinivasP.L. Process for the preparation of pantoprazole sodium.WO Patent 2006064249A22009
  69. AzizianH. EsmailnejadA. Fathi VavsariV. MaherniaS. AmanlouM. BalalaieS. Pantoprazole derivatives: Synthesis, urease inhibition assay and in silico molecular modeling studies.ChemistrySelect20205154580458710.1002/slct.202000578
     [Google Scholar]
  70. LinderR. Freeze-dried pantoprazole preparation and pantoprazole injection.US Patent 200300030582003
  71. BardouM. MartinJ. Pantoprazole: From drug metabolism to clinical relevance.Expert Opin. Drug Metab. Toxicol.20084447148310.1517/17425255.4.4.47118433349
     [Google Scholar]
  72. ShinJ.M. SachsG. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.Biochem. Pharmacol.200468112117212710.1016/j.bcp.2004.07.03515498502
     [Google Scholar]
  73. PooleP. PantoprazoleAJHP20015811999100810.1093/ajhp/58.11.999
     [Google Scholar]
  74. RayP.C. MittapelliV. RohatgiA. TyagiO.D. Efficient Synthesis of N ‐Oxide Derivatives: Substituted 2‐(2‐(Pyridyl‐ N ‐oxide)methylsulphinyl)benzimidazoles.Synth. Commun.200737172861286810.1080/00397910701470693
     [Google Scholar]
  75. SoudaS. UedaN. MiyazawaS. TagamiK. NomotoS. OkitaM. ShimomuraN. KanekoT. FujimotoM. MurakamiM. Pyridine derivatives having anti-ulcerative activity.US Patent 5045552A1991
  76. TagamiK. ChikuS. SohdaS. Synthesis of 14 C‐labelled sodium pariprazole (E3810).J. Labelled Comp. Radiopharm.199333984985210.1002/jlcr.2580330908
     [Google Scholar]
  77. JadhavR. MoreK. KhandekarD. YamgarR. SawantS. An efficient synthesis of rabeprazole sodium.Asian J. Pharm. Res.2011111316
     [Google Scholar]
  78. ReddyG.M. MukkantiK. BhaskarB.V. ReddyP.P. Synthesis of metabolites and related substances of rabeprazole, an anti-ulcerative drug.Synth. Commun.200839227829010.1080/00397910802372541
     [Google Scholar]
  79. VenkatramanS. Crystalline form Z of rabeprazole sodium and process for preparation thereof.US Patent 200401809352004
  80. PaceF. PallottaS. CasaliniS. PorroG.B. A review of rabeprazole in the treatment of acid-related diseases.Ther. Clin. Risk Manag.20073336337918488081
     [Google Scholar]
  81. JewellR. RabeprazoleIn: xPharm: The Comprehensive Pharmacology Reference20071510.1016/B978‑008055232‑3.62509‑7
     [Google Scholar]
  82. MarelliS. PaceF. Rabeprazole for the treatment of acid-related disorders.Expert Rev. Gastroenterol. Hepatol.20126442343510.1586/egh.12.1822928894
     [Google Scholar]
  83. MadanM.R.M. MahidharR.D. JyothirmaiK. RambabuP. AnkaR.E. RevathiS. DayasagarB. A novel review on anti-intestinal proton pump inhibitor: Rabeprazole.Pharmanest2013416675
     [Google Scholar]
  84. CarswellC.I. GoaK.L. Rabeprazole.Drugs200161152327235610.2165/00003495‑200161150‑0001611772142
     [Google Scholar]
  85. DadabhaiA. FriedenbergF.K. Rabeprazole: A pharmacologic and clinical review for acid-related disorders.Expert Opin. Drug Saf.20098111912610.1517/1474033080262289219236223
     [Google Scholar]
  86. PrakashA. FauldsD. RabeprazoleDrugs19985526126710.2165/00003495‑199855020‑00009
     [Google Scholar]
  87. SripathiS. BojjaR.R. KarnatiV.R. RajuV.V.N.K.V.P. KhuntM.D. An improved synthesis of antiulcerative drug: Tenatoprazole.Org. Process Res. Dev.200913480480610.1021/op800173u
     [Google Scholar]
  88. MatsuishiN. TakedaH. IizumiK. MurakamiK. HisamitsuA. Imidazo[4,5-b] pyridine compounds and pharmaceutical compositions containing same.US Patent 48085961989
  89. FaxiangZ. ShiyangT. YingZ. Novel method for preparing tenatoprazole.CN Patent 102304127A2012
  90. YamashitaS. EbinaK. Enantiomer of tenatoprazole and the use thereof in therapy.US 20060122216A12009
  91. AgerD. Industrial applications of asymmetric oxidations.Comprehensive Chirality201210412810.1016/B978‑0‑08‑095167‑6.00906‑X
     [Google Scholar]
  92. YanF. FanK.Q. ChiC. GuanJ. Synthesis of antiulcerative drug tenatoprazole.Adv. Mat. Res.2011233-235160164
     [Google Scholar]
  93. ReddyG.M. Prasada RajuV.V.N.K.V. BabuJ.M. PraveenC. KhuntM. MukkantiK. Pratap ReddyP. Synthesis and characterization of metabolites and potential impurities of the antiulcerative drug tenatoprazole.Synth. Commun.200838111725173610.1080/00397910801986192
     [Google Scholar]
  94. JanaK. GhoshS. WakchaureP.D. BandyopadhyayT. GangulyB. Probing the role of imidazopyridine and imidazophosphorine scaffolds to design novel proton pump inhibitor for H +, K + -ATPase: A DFT study.ACS Omega2019411311132110.1021/acsomega.8b02756
     [Google Scholar]
  95. GalmicheJ.P. Sacher-HuvelinS. Bruley des VarannesS. VavasseurF. TaccoenA. FiorentiniP. HomerinM. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40mg on intragastric pH in healthy volunteers.Aliment. Pharmacol. Ther.2006232810.1111/j.1365‑2036.2006.02943.x
     [Google Scholar]
  96. ScarpignatoC. PelosiniI. Review article: the opportunities and benefits of extended acid suppressionAliment Pharmacol Ther.2006232233410.1111/j.1365‑2036.2006.02945.x16700900
     [Google Scholar]
  97. SastryT.U. NageswararaoK. ReddyT.A. Identification and synthesis of impurities formed during ilaprazole preparation.Pharma Chem.201136360364
     [Google Scholar]
  98. Ilaprazole, IY-81149.2024Available from: https://www.drugfuture.com/synth/syndata.aspx?ID=228755
  99. JiaR. ZhangF. WuN. XuW. GaoH. LiuB. WangH. Accelerating development of benziamidazole-class proton pump inhibitors: A mechanism-based pk/pd model to optimize study design with ilaprazole as a case drug.Pharmaceutics202113339210.3390/pharmaceutics1303039233804279
     [Google Scholar]
  100. CorletoV.D. FestaS. Di GiulioE. AnnibaleB. Proton pump inhibitor therapy and potential long-term harm.Curr. Opin. Endocrinol. Diabetes Obes.20142113810.1097/MED.000000000000003124310148
     [Google Scholar]
  101. WangH. LangL. OuN. ShiR. HuH. HuP. JiangJ. Pharmacokinetics, pharmacodynamics and safety of multiple-infusion ilaprazole in healthy chinese subjects.Clin. Drug Investig.201636646347010.1007/s40261‑016‑0390‑227067231
     [Google Scholar]
  102. SavarinoE. OttonelloA. MartinucciI. DulbeccoP. SavarinoV. Ilaprazole for the treatment of gastro-esophageal reflux.Expert Opin. Pharmacother.201617152107211310.1080/14656566.2016.123238927598861
     [Google Scholar]
  103. RocheV.F. The chemically elegant proton pump inhibitors.Am. J. Pharm. Educ.200670510110.5688/aj7005101
     [Google Scholar]
  104. KühlerT.C. SwansonM. ShcherbuchinV. LarssonH. MellgårdB. SjöströmJ.E. Structure-activity relationship of 2-[[(2-pyridyl)methyl]thio]-1H- benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy.J. Med. Chem.199841111777178810.1021/jm970165r9599229
     [Google Scholar]
  105. KuehlerT.C. FryklundJ. BergmanN. WeilitzJ. LeeA. LarssonH. Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors.J. Med. Chem.199538254906491610.1021/jm00025a0088523404
     [Google Scholar]
  106. LindbergP. NordbergP. AlmingerT. BrändströmA. WallmarkB. The mechanism of action of the gastric acid secretion inhibitor omeprazole.J. Med. Chem.19862981327132910.1021/jm00158a0013016260
     [Google Scholar]
  107. Senn-BilfingerJ. The development of a new proton‐pump inhibitor: The case history of pantoprazole.Analogue-based Drug Discovery FischerJ. GanellinC.R. 200611513610.1002/3527608001.ch6
     [Google Scholar]
  108. LindbergP. CarlssonE. Esomeprazole in the framework of proton-pump inhibitor development.Analogue-Based Drug Discovery.Wiley-VCH20068111210.1002/3527608001
     [Google Scholar]
  109. FaheemM. RathaurA. PandeyA. Kumar SinghV. TiwariA.K. A review on the modern synthetic approach of benzimidazole candidate.ChemistrySelect20205133981399410.1002/slct.201904832
     [Google Scholar]
  110. AzumaH. BannoK. YoshimuraT. Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent.Br. J. Pharmacol.197658448348810.1111/j.1476‑5381.1976.tb08614.x63304
     [Google Scholar]
  111. SimonsF.E.R. LuciukG.H. BeckerA.B. GillespieC.A. Ketotifen: A new drug for prophylaxis of asthma in children.Ann. Allergy19824831451506121527
     [Google Scholar]
  112. De BenedictisF.M. De BenedictisD. CanonicaG.W. New oral H1 antihistamines in children: Facts and unmeet needs.Allergy200863101395140410.1111/j.1398‑9995.2008.01771.x18782118
     [Google Scholar]
  113. SaitoK. AbeN. ToyamaH. EjimaY. YamauchiM. MushiakeH. KazamaI. Second-generation histamine H1 receptor antagonists suppress delayed rectifier K+-channel currents in murine thymocytes.BioMed Res. Int.2019201911210.1155/2019/626195131183371
     [Google Scholar]
  114. CollierS.J. WuX. PohZ. RajkumarG.A. YetL. Alternative synthesis of bilastine.Synth. Commun.20114191394140210.1080/00397911.2010.486506
     [Google Scholar]
  115. DingH.X. LiuK.K.C. SakyaS.M. FlickA.C. O’DonnellC.J. Synthetic approaches to the 2011 new drugs.Bioorg. Med. Chem.201321112795282510.1016/j.bmc.2013.02.06123623674
     [Google Scholar]
  116. RaoM.D. VenugopalB. Improved process for prepration of bilastine using noval intermediate.WO Patent 20180423052018
  117. ReddyT.P. DussaN. MamidiS. PanasaM. ChavakulaR. PadmaM. Identification and synthesis of potential impurities of bilastine drug substance.Chem. Zvesti20227674137414510.1007/s11696‑022‑02157‑5
     [Google Scholar]
  118. RidoloE. MontagniM. BonzanoL. IncorvaiaC. CanonicaG.W. Bilastine: New insight into antihistamine treatment.Clin. Mol. Allergy20151311610.1186/s12948‑015‑0008‑x25878559
     [Google Scholar]
  119. WalshG.M. Chapter 15 - Antihistamines (H1 receptor antagonists).Side Effects of Drugs AnnualElsevier201429530710.1016/B978‑0‑444‑62635‑6.00015‑2
     [Google Scholar]
  120. Bilastine.2021Available from: https://www.practo.com/medicine-info/bilastine-5106-api
  121. VardanyanR.S. Antihistamine drugs.Synthesis of Essential DrugsElsevierAmsterdam200621923510.1016/B978‑044452166‑8/50016‑9
     [Google Scholar]
  122. deParrodiC.A. Quintero-CortésL. Sandoval-RamírezJ. Short synthesis of astemizole.Synth. Commun.199626173323332910.1080/00397919608004642
     [Google Scholar]
  123. RomanG. CrandallI.E. SzarekW.A. Synthesis and anti-Plasmodium activity of benzimidazole analogues structurally related to astemizole.ChemMedChem20138111795180410.1002/cmdc.20130017224022991
     [Google Scholar]
  124. VardanyanR. 4-substituted and 1,4-disubstituted piperidines.Piperidine-Based Drug DiscoveryElsevier201714722110.1016/B978‑0‑12‑805157‑3.00005‑3
     [Google Scholar]
  125. ShafieeA. Astemizole.Encyclopedia of ToxicologyElsevier20143rd ed33233510.1016/B978‑0‑12‑386454‑3.00694‑1
     [Google Scholar]
  126. Astemizole.2024Available from: https://www.pediatriconcall.com/drugs/astemizole/289
  127. PrakashA. LambH.M. Mizolastine: A review of its use in allergic rhinitis and chronic idiopathic urticaria.BioDrugs1998101416310.2165/00063030‑199810010‑0000418020585
     [Google Scholar]
  128. ManouryP. BinetJ. De-FosseG. 2-[4-Pyrimidin-2-yl-amino)piperidin-1-yl] benzimidazole compoundUS Patent 49122191990
  129. SelveN. PichatP.H. GoldhillJ. DepoortereH. ArbillaS. Pharmacological profile of mizolastine, a novel histamine H1 receptor antagonist. In: From Mast Cells and Basophils; Academic Press,2000625640
     [Google Scholar]
  130. TriggianiM. PalumboC. GentileM. GranataF. MaroneG. Antihistaminic and anti-inflammatory effects of mizolastine.Mast Cells and BasophilsAcademic Press200066567210.1021/jm00157a010
     [Google Scholar]
  131. LiJ. ChenW. PengC. ZhuW. LiuZ. ZhangW. SuJ. LiJ. ChenX. Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria.Pharmacogenomics J.2020201879310.1038/s41397‑019‑0094‑031406237
     [Google Scholar]
  132. IemuraR. KawashimaT. FukudaT. ItoK. TsukamotoG. Synthesis of 2-(4-substituted-1-piperazinyl)benzimidazoles as H1-antihistaminic agents.J. Med. Chem.19862971178118310.1021/jm00157a0102879912
     [Google Scholar]
  133. Wikimedia Commons contributors. Available from: https://commons.wikimedia.org/w/index.php?title=File:Emedastine_synthesis.png&oldid=505764972 (Accessed March 21, 2024).
  134. LiY. YuF. ZhuangS. Improved synthetic method and characterization of emedastine difumarate.Zuo Wu Xue Bao201330111285128810.3724/SP.J.1095.2013.20601
     [Google Scholar]
  135. MurotaH. KatayamaI. Emedastine difumarate: A review of its potential ameliorating effect for tissue remodeling in allergic diseases.Expert Opin. Pharmacother.200910111859186710.1517/1465656090307841019558341
     [Google Scholar]
  136. YanniJ.M. BarneyN.P. Chapter 11 - Ocular allergy: Clinical, therapeutic and drug discovery considerationsOcular TherapeuticsAcademic Press200823927410.1016/B978‑012370585‑3.50013‑3
     [Google Scholar]
  137. Emedastine difumarate drops - Uses, side effects, and more.Available from: https://www.webmd.com/drugs/2/drug-6499/emedastine-difumarate-ophthalmic-eye/details
  138. GriffinA.L. JaishankarP. GrandjeanJ.M. OlsonS.H. RensloA.R. BarabanS.C. Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome.Brain Commun.201911fcz00810.1093/braincomms/fcz00831667472
     [Google Scholar]
  139. Clemizole synthesis.2015Available from: https://en.wikipedia.org/wiki/File:Clemizole_synthesis.svg
  140. Clemizole Synthesis.2022Available from: https://commons.wikimedia.org/wiki/File:Clemizole_Synthesis.svg
  141. GuptaS.P. The medicinal chemistry of antihepatitis agents III.Studies on Hepatitis VirusesElsevier201813321010.1016/B978‑0‑12‑813330‑9.00007‑7
     [Google Scholar]
  142. MendezR. KabelaE. PastelinG. Martínez-LópezM. Sánchez-PérezS. Antiarrhythmic actions of clemizole as pharmacologic evidence for a circus movement mechanism in atrial flutter.Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol.1969262332533610.1007/BF005384344388778
     [Google Scholar]
  143. SiwachA. VermaP.K. Synthesis and therapeutic potential of imidazole containing compoundsBMC Chem.20211516910.1186/s13065‑020‑00730‑1
     [Google Scholar]
  144. SimonsF.E. SimonsK.J. Second-generation H1-receptor antagonists.Ann. Allergy1991661516, 191670985
     [Google Scholar]
  145. ScaglioneF. Safety profile of bilastine: 2nd generation H1-antihistamines.Eur. Rev. Med. Pharmacol. Sci.201216141999200523242729
     [Google Scholar]
  146. OrjalesA. RubioV. BordellM. CanalG. InnerárityA. BerisaA. LabeagaL. MosqueraR. Synthesis and histamine H1 receptor affinity of new analogues to bilastine.US Patent 5877187
  147. FoyeW.O. LemkeT.L. WilliamsD.A. Antihistamines and related antiallergic and antiulcer agents.Foye's Principles of Medicinal ChemistryWolters Kluwer: Lippincott Williams & Wilkins6th ed20021004
     [Google Scholar]
  148. BrzezińskaE. KośkaG. A structure–activity relationship study of compounds with antihistamine activity.Biomed. Chromatogr.200620101004101610.1002/bmc.62116506293
     [Google Scholar]
  149. VlahakisJ.Z. VukomanovicD. NakatsuK. SzarekW.A. Selective inhibition of heme oxygenase-2 activity by analogs of 1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzimidazole (clemizole): Exploration of the effects of substituents at the N-1 position.Bioorg. Med. Chem.201321216788679510.1016/j.bmc.2013.07.05024021581
     [Google Scholar]
  150. TrailokyaA. RoyS. Bilastine - Novel anti histamine drug for allergic rhinitis.IP Indian J. Immunol. Respir. Med.20227161010.18231/j.ijirm.2022.003
     [Google Scholar]
  151. YibirinM. De OliveiraD. ValeraR. PlittA.E. LutgenS. Adverse effects associated with proton pump inhibitor use.Cureus2021131e1275910.7759/cureus.1275933614352
     [Google Scholar]
  152. NehraA.K. AlexanderJ.A. LoftusC.G. NehraV. Proton pump inhibitors: Review of emerging concerns.Mayo Clin. Proc.201893224024610.1016/j.mayocp.2017.10.02229406201
     [Google Scholar]
  153. ShinJ.M. SachsG. Pharmacology of proton pump inhibitors.Curr. Gastroenterol. Rep.200810652853410.1007/s11894‑008‑0098‑419006606
     [Google Scholar]
  154. FossmarkR. MartinsenT.C. WaldumH.L. Adverse effects of proton pump inhibitors-evidence and plausibility.Int. J. Mol. Sci.20192020520310.3390/ijms2020520331640115
     [Google Scholar]
  155. HaastrupP.F. ThompsonW. SøndergaardJ. JarbølD.E. Side effects of long-term proton pump inhibitor use: A review.Basic Clin. Pharmacol. Toxicol.2018123211412110.1111/bcpt.1302329658189
     [Google Scholar]
  156. CastellanaC. PecereS. FurnariM. TeleseA. MatteoM.V. HaidryR. EusebiL.H. Side effects of long-term use of proton pump inhibitors: Practical considerations.Pol. Arch. Intern. Med.2021131654154910.20452/pamw.1599733982542
     [Google Scholar]
  157. SchoenfeldA.J. GradyD. Adverse effects associated with proton pump inhibitors.JAMA Intern. Med.2016176217217410.1001/jamainternmed.2015.792726751904
     [Google Scholar]
  158. SchubertM.L. Adverse effects of proton pump inhibitors.Curr. Opin. Gastroenterol.201834645145710.1097/MOG.000000000000047130102612
     [Google Scholar]
  159. AnaisR. AndreadisK. BayoumiA. MatthewK. BelafskyP. side effects of proton pump inhibitors: What are patients concerns?J. Voice2020355809.e15809.e2010.1016/j.jvoice.2020.01.018
     [Google Scholar]
  160. EusebiL.H. RabittiS. ArtesianiM.L. GelliD. MontagnaniM. ZagariR.M. BazzoliF. Proton pump inhibitors: Risks of long‐term use.J. Gastroenterol. Hepatol.20173271295130210.1111/jgh.1373728092694
     [Google Scholar]
  161. VaeziM.F. YangY.X. HowdenC.W. Complications of proton pump inhibitor therapy.Gastroenterology20171531354810.1053/j.gastro.2017.04.04728528705
     [Google Scholar]
  162. FeinM.N. FischerD.A. O’KeefeA.W. SussmanG.L. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria.Allergy Asthma Clin. Immunol.20191516110.1186/s13223‑019‑0375‑931582993
     [Google Scholar]
  163. Kumaş-KulualpM. GepdiremenA. KarataşE. EşrefoğluM. Clemizole hydrochloride, a potent TRPC5 calcium channel inhibitor, prevents cisplatin‐induced nephrotoxicity in Spraque–Dawley rats.J. Biochem. Mol. Toxicol.2023377e2337210.1002/jbt.2337237102204
     [Google Scholar]
  164. Singh RandhawaA. Mohd NoorN. Md DaudM.K. AbdullahB. Efficacy and safety of bilastine in the treatment of allergic rhinitis: A systematic review and meta-analysis.Front. Pharmacol.202212173120110.3389/fphar.2021.73120135082662
     [Google Scholar]
  165. BachertC. VovolisV. MargariP. Murrieta-AguttesM. SantoniJ.P. Mizolastine in the treatment of seasonal allergic rhinoconjunctivitis: A European clinical experience with 5408 patients managed in daily practice (PANEOS SAR Study).Allergy200156765365910.1034/j.1398‑9995.2001.00756.x11421924
     [Google Scholar]
  166. SastreJ. Ebastine in allergic rhinitis and chronic idiopathic urticaria.Allergy200863s8912010.1111/j.1398‑9995.2008.01897.x19032340
     [Google Scholar]
  167. LiL. LiuR. PengC. ChenX. LiJ. Pharmacogenomics for the efficacy and side effects of antihistamines.Exp. Dermatol.2022317993100410.1111/exd.1460235538735
     [Google Scholar]
  168. Skrzydło-RadomańskaB. RadwanP. Dexlansoprazole – A new-generation proton pump inhibitor.Prz. Gastroenterol.20154419119610.5114/pg.2015.5610926759624
     [Google Scholar]
  169. MacorJ.E. Cumulative nice introduction index.Annual Reports in Medicinal ChemistryAcademic PressUSA201153155110.1016/B978‑0‑12‑386009‑5.00035‑7
     [Google Scholar]
  170. Bilastine (international).Available from: https://www.drugs.com/international/bilastine.html
  171. KennewellP.D. 1.03 - Major drug introductions. In: Comprehensive Medicinal Chemistry II. 2007, Vol. 1, pp. 97-249.10.1016/B0‑08‑045044‑X/00003‑1
     [Google Scholar]
  172. ZierzP. GreitherH. Clinical evaluation of allercur, a new antihistaminic.Arztl. Wochensch.195273070470712976278
     [Google Scholar]
  173. Emedastine difumarate.2024Available from: https://synapse.patsnap.com/drug/ee4b35d10032477db9a634acf6ae4707
  174. MatsumotoS. YamazoeY. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine.Br. J. Clin. Pharmacol.200151213314210.1111/j.1365‑2125.2001.01292.x11259984
     [Google Scholar]
  175. ZhouZ. VorperianV.R. GongQ. ZhangS. JanuaryC.T. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole.J. Cardiovasc. Electrophysiol.199910683684310.1111/j.1540‑8167.1999.tb00264.x10376921
     [Google Scholar]
  176. CharlesO. OnakpoyaI. BenipalS. WoodsH. BaliA. AronsonJ.K. HeneghanC. PersaudN. Withdrawn medicines included in the essential medicines lists of 136 countries.PLoS One20191412e022542910.1371/journal.pone.022542931791048
     [Google Scholar]
/content/journals/mrmc/10.2174/0113895575329633240928163509
Loading
An Outline on Benzimidazole Containing Marketed Drugs with Proton Pump Inhibitor and H1 Receptor Antagonist Activities
Mini Rev Med Chem 25, 440 (2025); https://doi.org/10.2174/0113895575329633240928163509
/content/journals/mrmc/10.2174/0113895575329633240928163509
/content/journals/mrmc/10.2174/0113895575329633240928163509
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Benzimidazole moiety; H1 receptor antagonist; marketed drugs; MOA; PPIs; SAR; synthetic route; therapeutical uses

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test